Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 February 2021 | Story Leonie Bolleurs | Photo Stephen Collett
Prof Lizette de Wet
Prof Lizette de Wet is of the opinion that there is no gender distinction between what women and men could achieve in the field of Computer Science and Informatics.

“I consider obtaining my PhD while balancing my work, my marriage, and two young daughters (who did not sleep through before reaching age four!) as one of my biggest achievements,” says Prof Lizette de Wet, Associate Professor in the Department of Computer Science and Informatics at the University of the Free State (UFS).

Many firsts

Her achievements in the field include much more than the PhD referred to. On 11 February, International Day of Women and Girls in Science, the UFS celebrates her for pioneering the human-computer interaction (HCI) research environment, specifically the evaluation of usability and user experience in diverse application areas, where she has experienced and established many firsts.

Prof De Wet was one of the first students to complete a master’s degree in this discipline at UNISA (1994). She says the external examiner for her master’s was from the University of York in the UK, as expertise in South Africa was still lacking at the time.

In the Department of Computer Science and Informatics at the UFS, she established the HCI research area. This involved undertaking research projects in the discipline and developing curricula for a second-year module, an honours module, and a master’s module. 

“The second-year module was also one of two modules on campus to first use iPads in class to assist in a blended learning approach,” she says. 

 

Taking the human being into consideration is much more important than simply concentrating on the programming code that needs to be written.– Prof Lizette de Wet


A woman’s contribution

Prof De Wet believes that in the research field of HCI, the focus is on the user and his/her overall user experience (including emotions, feelings, and competence) when using computers. “Taking the human being into consideration is much more important than simply concentrating on the programming code that needs to be written.”

Whether the human being writing the code is male or female, does not matter. Prof De Wet is of the opinion that there is no gender distinction between what women and men could achieve in the field of Computer Science and Informatics. 

“Although the students are still predominantly male, in the past few years more and more female students have enrolled for our postgraduate studies and completed it successfully, some of them with exceptional marks. In South-Africa, many women are making their mark in this discipline by being heads of departments at universities or in the private sector, by chairing national and international conferences, and by publishing ground-breaking research,” she adds.

Success with virtual reality

Over the past few years, Prof De Wet has concentrated on using brain-computer interfaces (BCIs) and virtual reality in her research. By the end of 2020, she had successfully supervised 11 master’s students and four PhD students, with one of the master’s students delivering ground-breaking research using virtual reality in the training of nursing students.

She elaborates: “The prototype involved virtually examining and evaluating a patient (with a foreign object lodged in a lung) in a virtual ward while wearing an Oculus Rift headset. The evaluation results were extremely positive and will be continued as a PhD study to investigate how to attempt to relieve motion sickness in an immersive virtual clinical simulation.”

Starting out as someone who never had the opportunity to lay her eyes on a computer during her school years, Prof De Wet is of the opinion that in South Africa – being a Third World country – there are numerous opportunities to make computers accessible to rural communities, and even to the large senior population who did not grow up with technology and might fear it.

With her passion for the profession, she not only delivers pioneering work, but also trains professionals in computer sciences who will contribute to a better tomorrow. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept